Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iruplinalkib Neoadjuvant Therapy in ALK+ NSCLC
NCT06282536Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06282536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06282536.